Lixa Pty Ltd
Lixa is a biotech company dedicated to resolving recurring microbial infections and contaminations by addressing the global challenge of antimicrobial resistance (AMR). The company is pioneering a technology platform called NeoX™, which aims to restore the effectiveness of existing antimicrobials and biocides against resistant bacteria. Lixa's mission is to develop scalable, cost-effective solutions that can be applied across various sectors, including human, animal, plant, marine, and industrial applications, to combat AMR and improve global health.
Industries
Nr. of Employees
small (1-50)
Products
Resistance‑breaking antibiofilm molecule platform (lead inhaled candidate)
A platform of small molecules that dismantle bacterial biofilms and disable resistance mechanisms to restore the effectiveness of existing antibiotics and disinfectants; lead candidate formulated for inhalation with Phase I safety data.
Resistance‑breaking antibiofilm molecule platform (lead inhaled candidate)
A platform of small molecules that dismantle bacterial biofilms and disable resistance mechanisms to restore the effectiveness of existing antibiotics and disinfectants; lead candidate formulated for inhalation with Phase I safety data.
Expertise Areas
- Antibiofilm therapeutics development
- Early‑phase clinical development (Phase I)
- Molecular microbiology and biofilm biology
- Antimicrobial synergy screening
Key Technologies
- Antibiofilm small‑molecule platform
- Inhaled drug delivery via nebuliser
- Biofilm disruption and quantification assays
- Synergy screening between antimicrobials
Key People
CEO, Managing Director
Chair
Director
Director
CFO
CEO, Managing Director
Chair
Director
Director
CFO
Investors
Series A - Lixa
$1,480,199 funded.
Announced on 2022-09-06.
Series A - Lixa
$1,480,199 funded.
Announced on 2022-09-06.
News & Updates
A new training Centre led by The University of Queensland is partnering with industry to tackle the global crisis of antimicrobial-resistant infections, which affect humans, animals and the environment.
Lixa has received Human Research Ethics Committee (HREC) approval to commence its first human trial - a Phase I clinical trial assessing the safety and tolerability of NeoX™ in an inhaled formulation.
Lixa has received an Innovation Booster grant from the Department of Jobs, Tourism, Science and Innovation and the WA Government's New Industries Fund.
Lixa is on a mission to resolve recurring microbial infections and contaminations by developing a novel approach that makes resistant bacteria vulnerable to antibiotics and the immune system again.
Mila – Quebec AI Institute and Lixa have announced a partnership to combine Lixa’s antibiofilm knowledge with Mila’s expertise in artificial intelligence to combat antimicrobial resistance.
Lixa was announced as the winner of the WA Innovator of the Year 2022 Wesfarmers Wellbeing Platinum award.
A new training Centre led by The University of Queensland is partnering with industry to tackle the global crisis of antimicrobial-resistant infections, which affect humans, animals and the environment.
Lixa has received Human Research Ethics Committee (HREC) approval to commence its first human trial - a Phase I clinical trial assessing the safety and tolerability of NeoX™ in an inhaled formulation.
Lixa has received an Innovation Booster grant from the Department of Jobs, Tourism, Science and Innovation and the WA Government's New Industries Fund.
Lixa is on a mission to resolve recurring microbial infections and contaminations by developing a novel approach that makes resistant bacteria vulnerable to antibiotics and the immune system again.
Mila – Quebec AI Institute and Lixa have announced a partnership to combine Lixa’s antibiofilm knowledge with Mila’s expertise in artificial intelligence to combat antimicrobial resistance.
Lixa was announced as the winner of the WA Innovator of the Year 2022 Wesfarmers Wellbeing Platinum award.